Zyclara filed in Europe

Zyclara filed in Europe

The marketing authorization application for the patented product Zyclara
(imiquimod 3.75% cream) has been filed with the European Medicines
Agency (EMA). Zyclara has been documented for once-daily topical
treatment of actinic keratosis (AK).

Zyclara expands the treatment area to the full face or balding scalp and
could become a first line therapy for AK. More than 1,400 patients have
been included in seven clinical studies.

“Zyclara will strengthen Meda's dermatology franchise in Europe. We look
forward to provide AK patients with a new product that can treat larger
areas of the skin”, says Anders Lönner, CEO of Meda.

For further inquiries, please contact:

Anders Larnholt, Vice President Corporate Development & IR ph: 46
709-458 878